Last reviewed · How we verify
NCT00027677
Phase I Study To Determine The Safety Of Halofuginone In Patients With A Solid Progressive Tumor
Phase 1 trial testing halofuginone hydrobromide in Unspecified Adult Solid Tumor, Protocol Specific in 25 participants. Completed.
1 February 2004
Quick facts
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 1 August 2001 |
| Primary completion | 1 February 2004 |
| Sites | 3 locations across Belgium, Netherlands |
Drugs / interventions tested
- halofuginone hydrobromide — full drug profile →
Conditions studied
- Unspecified Adult Solid Tumor, Protocol Specific — all drugs for Unspecified Adult Solid Tumor, Protocol Specific →
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC — full company profile →
Who can join
18 and older, any sex, with Unspecified Adult Solid Tumor, Protocol Specific. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Halofuginone hydrobromide may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of halofuginone hydrobromide in treating patients who have progressive advanced solid tumors.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer.
Zhang M, Zhang B. · · 2025 · cited 69× · PMID 40211368 · DOI 10.1186/s40164-025-00647-2 -
Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer.
Telkoparan-Akillilar P, Panieri E, Cevik D, Suzen S, et al · · 2021 · cited 67× · PMID 33808001 · DOI 10.3390/molecules26051417 -
Exploiting Mitochondrial Vulnerabilities to Trigger Apoptosis Selectively in Cancer Cells.
Nguyen C, Pandey S. · · 2019 · cited 64× · PMID 31261935 · DOI 10.3390/cancers11070916 -
Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment.
Zhang J, Xu HX, Zhu JQ, Dou YX, et al · · 2023 · cited 49× · PMID 37416770 · DOI 10.7150/ijbs.82401 -
The integrated stress response in cancer progression: a force for plasticity and resistance.
Lines CL, McGrath MJ, Dorwart T, Conn CS. · · 2023 · cited 46× · PMID 37601686 · DOI 10.3389/fonc.2023.1206561 -
Multiple aspects of matrix stiffness in cancer progression.
Mancini A, Gentile MT, Pentimalli F, Cortellino S, et al · · 2024 · cited 30× · PMID 39015505 · DOI 10.3389/fonc.2024.1406644 -
Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma.
Devan AR, Pavithran K, Nair B, Murali M, et al · · 2022 · cited 25× · PMID 36185626 · DOI 10.3748/wjg.v28.i36.5250 -
Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications.
Raja A, Haq F. · · 2022 · cited 20× · PMID 34623518 · DOI 10.1007/s00432-021-03826-w
Verify or expand the search:
- PubMed search for NCT00027677
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Unspecified Adult Solid Tumor, Protocol Specific
Currently open trials in the same condition.
- NCT02112565 — RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Stand · Phase 1 · active not recruiting
- NCT02293954 — Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer · NA · active not recruiting
- NCT00477958 — Assessment Tool for Older Patients With Cancer · NA · active not recruiting
Other European Organisation for Research and Treatment of Cancer - EORTC trials
Trials by the same sponsor.
- NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
- NCT06978062 — Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment · Phase 1 · not yet recruiting
- NCT06809322 — Vorasidenib Maintenance for IDH Mutant Astrocytoma · Phase 3 · recruiting
- NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, · NA · not yet recruiting
- NCT06783348 — Radiopharmaceutical Treatment of Advanced Kidney Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00027677 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Organisation for Research and Treatment of Cancer - EORTC
- Last refreshed: 23 July 2012
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00027677.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing